Advertisement
Advertisement
U.S. markets close in 5 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (JAM1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.0641-0.0285 (-30.78%)
As of 08:00AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0926
Open0.0641
Bid0.0638 x 4074100
Ask0.0923 x 2558200
Day's Range0.0641 - 0.0641
52 Week Range0.0638 - 0.3525
Volume1,079
Avg. Volume8,048
Market Cap30.676M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for JAM1.F

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 million. The Offering was co-led by Research Capital Corporation and Echelon Wealth Partners Inc. as co-lead agents and joint bookrunners (the "Age

    • GlobeNewswire

      REPEAT – Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of Units

      NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the price of its marketed public offering (the “Offering”) of units of the Company (the “Units”) previously announced on December 1, 2021. Pursuant to the Offering, the Company intends to issue Unit

    • GlobeNewswire

      Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of Units

      NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the price of its marketed public offering (the “Offering”) of units of the Company (the “Units”) previously announced on December 1, 2021. Pursuant to the Offering, the Company intends to issue Unit

    Advertisement
    Advertisement